Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 4.90
ALIOF's Cash to Debt is ranked lower than
65% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: 56.40 vs. ALIOF: 4.90 )
Ranked among companies with meaningful Cash to Debt only.
ALIOF' s 10-Year Cash to Debt Range
Min: 2.7   Max: N/A
Current: 4.9

Equity to Asset 0.72
ALIOF's Equity to Asset is ranked higher than
55% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ALIOF: 0.72 )
Ranked among companies with meaningful Equity to Asset only.
ALIOF' s 10-Year Equity to Asset Range
Min: 0.5   Max: 0.72
Current: 0.72

0.5
0.72
Interest Coverage 58.07
ALIOF's Interest Coverage is ranked lower than
85% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALIOF: 58.07 )
Ranked among companies with meaningful Interest Coverage only.
ALIOF' s 10-Year Interest Coverage Range
Min: 0.3   Max: 9999.99
Current: 58.07

0.3
9999.99
F-Score: 7
Z-Score: 14.85
M-Score: -2.36
WACC vs ROIC
8.87%
63.63%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 30.29
ALIOF's Operating margin (%) is ranked higher than
92% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -73.33 vs. ALIOF: 30.29 )
Ranked among companies with meaningful Operating margin (%) only.
ALIOF' s 10-Year Operating margin (%) Range
Min: 0.68   Max: 29.11
Current: 30.29

0.68
29.11
Net-margin (%) 31.22
ALIOF's Net-margin (%) is ranked higher than
92% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -71.50 vs. ALIOF: 31.22 )
Ranked among companies with meaningful Net-margin (%) only.
ALIOF' s 10-Year Net-margin (%) Range
Min: -8.15   Max: 30.33
Current: 31.22

-8.15
30.33
ROE (%) 33.55
ALIOF's ROE (%) is ranked higher than
96% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. ALIOF: 33.55 )
Ranked among companies with meaningful ROE (%) only.
ALIOF' s 10-Year ROE (%) Range
Min: -8.85   Max: 53.58
Current: 33.55

-8.85
53.58
ROA (%) 23.73
ALIOF's ROA (%) is ranked higher than
96% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: -23.47 vs. ALIOF: 23.73 )
Ranked among companies with meaningful ROA (%) only.
ALIOF' s 10-Year ROA (%) Range
Min: -5.18   Max: 21.05
Current: 23.73

-5.18
21.05
ROC (Joel Greenblatt) (%) 125.13
ALIOF's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. ALIOF: 125.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALIOF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 2.31   Max: 174.15
Current: 125.13

2.31
174.15
Revenue Growth (3Y)(%) 3.70
ALIOF's Revenue Growth (3Y)(%) is ranked higher than
54% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. ALIOF: 3.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALIOF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -25.8   Max: 21.5
Current: 3.7

-25.8
21.5
EBITDA Growth (3Y)(%) 131.30
ALIOF's EBITDA Growth (3Y)(%) is ranked higher than
99% of the 426 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. ALIOF: 131.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALIOF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -48.4   Max: 131.3
Current: 131.3

-48.4
131.3
» ALIOF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ALIOF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 24.40
ALIOF's P/E(ttm) is ranked higher than
71% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 39.30 vs. ALIOF: 24.40 )
Ranked among companies with meaningful P/E(ttm) only.
ALIOF' s 10-Year P/E(ttm) Range
Min: 13.52   Max: 66.51
Current: 24.4

13.52
66.51
Forward P/E 19.46
ALIOF's Forward P/E is ranked higher than
95% of the 314 Companies
in the Global Biotechnology industry.

( Industry Median: 21.19 vs. ALIOF: 19.46 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 24.60
ALIOF's PE(NRI) is ranked higher than
70% of the 212 Companies
in the Global Biotechnology industry.

( Industry Median: 38.10 vs. ALIOF: 24.60 )
Ranked among companies with meaningful PE(NRI) only.
ALIOF' s 10-Year PE(NRI) Range
Min: 13.54   Max: 66.51
Current: 24.6

13.54
66.51
P/B 7.60
ALIOF's P/B is ranked lower than
70% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. ALIOF: 7.60 )
Ranked among companies with meaningful P/B only.
ALIOF' s 10-Year P/B Range
Min: 2.35   Max: 7.66
Current: 7.6

2.35
7.66
P/S 7.70
ALIOF's P/S is ranked higher than
65% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 11.92 vs. ALIOF: 7.70 )
Ranked among companies with meaningful P/S only.
ALIOF' s 10-Year P/S Range
Min: 1.96   Max: 16.68
Current: 7.7

1.96
16.68
PFCF 26.20
ALIOF's PFCF is ranked higher than
65% of the 220 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. ALIOF: 26.20 )
Ranked among companies with meaningful PFCF only.
ALIOF' s 10-Year PFCF Range
Min: 8.65   Max: 2760
Current: 26.2

8.65
2760
POCF 25.09
ALIOF's POCF is ranked higher than
62% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 31.64 vs. ALIOF: 25.09 )
Ranked among companies with meaningful POCF only.
ALIOF' s 10-Year POCF Range
Min: 8.43   Max: 240
Current: 25.09

8.43
240
EV-to-EBIT 22.84
ALIOF's EV-to-EBIT is ranked higher than
65% of the 206 Companies
in the Global Biotechnology industry.

( Industry Median: 30.27 vs. ALIOF: 22.84 )
Ranked among companies with meaningful EV-to-EBIT only.
ALIOF' s 10-Year EV-to-EBIT Range
Min: -53.3   Max: 261.7
Current: 22.84

-53.3
261.7
PEG 1.67
ALIOF's PEG is ranked higher than
71% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 2.33 vs. ALIOF: 1.67 )
Ranked among companies with meaningful PEG only.
ALIOF' s 10-Year PEG Range
Min: 0   Max: 4.8
Current: 1.67

0
4.8
Shiller P/E 46.30
ALIOF's Shiller P/E is ranked lower than
51% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 43.00 vs. ALIOF: 46.30 )
Ranked among companies with meaningful Shiller P/E only.
ALIOF' s 10-Year Shiller P/E Range
Min: 30.5   Max: 46.5
Current: 46.3

30.5
46.5
Current Ratio 2.74
ALIOF's Current Ratio is ranked lower than
65% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. ALIOF: 2.74 )
Ranked among companies with meaningful Current Ratio only.
ALIOF' s 10-Year Current Ratio Range
Min: 1.75   Max: 3.95
Current: 2.74

1.75
3.95
Quick Ratio 2.66
ALIOF's Quick Ratio is ranked lower than
63% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ALIOF: 2.66 )
Ranked among companies with meaningful Quick Ratio only.
ALIOF' s 10-Year Quick Ratio Range
Min: 1.7   Max: 3.8
Current: 2.66

1.7
3.8
Days Inventory 104.79
ALIOF's Days Inventory is ranked higher than
55% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 115.80 vs. ALIOF: 104.79 )
Ranked among companies with meaningful Days Inventory only.
ALIOF' s 10-Year Days Inventory Range
Min: 88.91   Max: 123.11
Current: 104.79

88.91
123.11

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.01
ALIOF's Dividend Yield is ranked lower than
51% of the 217 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. ALIOF: 1.01 )
Ranked among companies with meaningful Dividend Yield only.
ALIOF' s 10-Year Dividend Yield Range
Min: 0.9   Max: 2.7
Current: 1.01

0.9
2.7
Dividend Payout 0.22
ALIOF's Dividend Payout is ranked higher than
74% of the 117 Companies
in the Global Biotechnology industry.

( Industry Median: 0.36 vs. ALIOF: 0.22 )
Ranked among companies with meaningful Dividend Payout only.
ALIOF' s 10-Year Dividend Payout Range
Min: 0.47   Max: 1.14
Current: 0.22

0.47
1.14
Dividend growth (3y) 14.50
ALIOF's Dividend growth (3y) is ranked higher than
73% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. ALIOF: 14.50 )
Ranked among companies with meaningful Dividend growth (3y) only.
ALIOF' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 14.5
Current: 14.5

0
14.5
Yield on cost (5-Year) 1.00
ALIOF's Yield on cost (5-Year) is ranked lower than
58% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.36 vs. ALIOF: 1.00 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ALIOF' s 10-Year Yield on cost (5-Year) Range
Min: 0.9   Max: 2.7
Current: 1

0.9
2.7
Share Buyback Rate 0.70
ALIOF's Share Buyback Rate is ranked higher than
93% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: -11.40 vs. ALIOF: 0.70 )
Ranked among companies with meaningful Share Buyback Rate only.
ALIOF' s 10-Year Share Buyback Rate Range
Min: 1.7   Max: -81.8
Current: 0.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 38.20
ALIOF's Price/Net Cash is ranked lower than
86% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 9.70 vs. ALIOF: 38.20 )
Ranked among companies with meaningful Price/Net Cash only.
ALIOF' s 10-Year Price/Net Cash Range
Min: 11.79   Max: 75.62
Current: 38.2

11.79
75.62
Price/Net Current Asset Value 35.70
ALIOF's Price/Net Current Asset Value is ranked lower than
85% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 15.30 vs. ALIOF: 35.70 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALIOF' s 10-Year Price/Net Current Asset Value Range
Min: 4.58   Max: 21.66
Current: 35.7

4.58
21.66
Price/Tangible Book 10.90
ALIOF's Price/Tangible Book is ranked lower than
74% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. ALIOF: 10.90 )
Ranked among companies with meaningful Price/Tangible Book only.
ALIOF' s 10-Year Price/Tangible Book Range
Min: 2.98   Max: 10.28
Current: 10.9

2.98
10.28
Price/DCF (Projected) 3.20
ALIOF's Price/DCF (Projected) is ranked higher than
65% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALIOF: 3.20 )
Ranked among companies with meaningful Price/DCF (Projected) only.
ALIOF' s 10-Year Price/DCF (Projected) Range
Min: 1.41   Max: 2.85
Current: 3.2

1.41
2.85
Price/Median PS Value 2.20
ALIOF's Price/Median PS Value is ranked lower than
68% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. ALIOF: 2.20 )
Ranked among companies with meaningful Price/Median PS Value only.
ALIOF' s 10-Year Price/Median PS Value Range
Min: 0.57   Max: 4.45
Current: 2.2

0.57
4.45
Price/Graham Number 3.40
ALIOF's Price/Graham Number is ranked higher than
60% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ALIOF: 3.40 )
Ranked among companies with meaningful Price/Graham Number only.
ALIOF' s 10-Year Price/Graham Number Range
Min: 1.4   Max: 3.02
Current: 3.4

1.4
3.02
Earnings Yield (Greenblatt) 4.40
ALIOF's Earnings Yield (Greenblatt) is ranked higher than
92% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. ALIOF: 4.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
ALIOF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 13.3
Current: 4.4

0.4
13.3

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:ATLNE.Switzerland, ATLN.Switzerland, ACT.Germany, 0QMN.UK,
Actelion Ltd was founded on December 17, 1997 and is headquartered in Allschwil, Switzerland. The Company is a biopharmaceutical company, that engages in the discovery, development, and commercialization of low molecular weight drugs for unmet medical needs. It is engaged in the field of pulmonary arterial hypertension (PAH). Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Its products portfolio includes Opsumit (Macitentan), Tracleer (Bosentan), Valchlor (Mechlorethamine), Zavesca (Miglustat), Veletri (Epoprostenol For Injection), and Ventavis (Iloprost).
» More Articles for ALIOF

Headlines

Articles On GuruFocus.com
Actelion Still On Growth Track Feb 18 2015 

More From Other Websites
Celldex Glioblastoma Vaccine Hits Phase II Primary Endpoint - Analyst Blog Jun 02 2015
Novartis Presents Data on Leukemia & Lung Cancer Drugs - Analyst Blog Jun 02 2015
Gilead Reveals Encouraging Data from Leukemia Study - Analyst Blog Jun 01 2015
Bristol-Myers' Opdivo Superior to Standard-of-Care Therapies - Analyst Blog Jun 01 2015
Stemline Therapeutics (STML) Jumps: Stock Rises 7.2% - Tale of the Tape Jun 01 2015
Peregrine Pharmaceuticals, Inc. (PPHM) in Focus: Stock Jumps 5.2% - Tale of the Tape Jun 01 2015
Pacira-FDA Meet for Exparel's Nerve Block Label Expansion - Analyst Blog May 29 2015
Is CVS Health (CVS) Worth Adding to Your Portfolio Now? - Analyst Blog May 29 2015
Gilead's New HIV Combination Drug under Review in the EU - Analyst Blog May 29 2015
Teva Settles Provigil Drug Delay Charge with FTC for $1.2B - Analyst Blog May 29 2015
XOMA Corp Looks Good: Stock Gains 7.8% in Session - Tale of the Tape May 29 2015
Amarin (AMRN) in Focus: Stock Surges 19% in Session - Tale of the Tape May 29 2015
Actavis' Viberzi Gets FDA Nod for Irritable Bowel Syndrome - Analyst Blog May 28 2015
Qiagen Launches Clinical Insight Bioinformatics Platform - Analyst Blog May 28 2015
Valeant Pharmaceuticals Gets FDA Nod for Xifaxan for IBS-D - Analyst Blog May 28 2015
GlobeImmune-Gilead's Hepatitis B Drug Fails in Phase II - Analyst Blog May 28 2015
Juno Therapeutics, Editas Ink Cancer Immunotherapy Deal - Analyst Blog May 28 2015
Alnylam (ALNY) Begins Phase I Study on Liver Disease Drug - Analyst Blog May 27 2015
Aegerion's Juxtapid Successful in Phase III Japanese Study - Analyst Blog May 27 2015
Genomic's Prostate Cancer Test Recommended by Palmetto - Analyst Blog May 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK